{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T11:16:29Z","timestamp":1786965389686,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T00:00:00Z","timestamp":1604016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T00:00:00Z","timestamp":1604016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s12325-020-01522-8","type":"journal-article","created":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T20:02:46Z","timestamp":1604088166000},"page":"366-385","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Epidemiology and Treatment of Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis in Germany: A Real-World Evidence Study"],"prefix":"10.1007","volume":"38","author":[{"given":"Claudia","family":"Grellmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Dombrowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Fabricius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Suruki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sheahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Joeres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,30]]},"reference":[{"issue":"5\u20136","key":"1522_CR1","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1007\/s00103-013-1687-4","volume":"56","author":"J Fuchs","year":"2013","unstructured":"Fuchs J, Rabenberg M, Scheidt-Nave C. Prevalence of selected musculoskeletal conditions in Germany: results of the German health interview and examination survey for adults (DEGS1). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013;56(5\u20136):678\u201386.","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"issue":"4","key":"1522_CR2","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s40265-014-0191-y","volume":"74","author":"PJ Mease","year":"2014","unstructured":"Mease PJ, Armstrong AW. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs. 2014;74(4):423\u201341.","journal-title":"Drugs"},{"issue":"1","key":"1522_CR3","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s40744-016-0029-z","volume":"3","author":"A Kavanaugh","year":"2016","unstructured":"Kavanaugh A, Helliwell P, Ritchlin CT. Psoriatic arthritis and burden of disease: patient perspectives from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey. Rheumatol Ther. 2016;3(1):91\u2013102.","journal-title":"Rheumatol Ther"},{"issue":"Suppl 2","key":"1522_CR4","first-page":"ii14","volume":"64","author":"DD Gladman","year":"2005","unstructured":"Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(Suppl 2):ii14\u2013ii17.","journal-title":"Ann Rheum Dis."},{"issue":"5","key":"1522_CR5","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.jaad.2008.02.040","volume":"58","author":"A Gottlieb","year":"2008","unstructured":"Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2 Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58(5):851\u201364.","journal-title":"J Am Acad Dermatol."},{"issue":"2","key":"1522_CR6","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2340\/00015555-0770","volume":"90","author":"M Augustin","year":"2010","unstructured":"Augustin M, Reich K, Glaeske G, Schaefer I, Radtke M. Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm Venereol. 2010;90(2):147\u201351.","journal-title":"Acta Derm Venereol"},{"key":"1522_CR7","unstructured":"World Health Organisation. Global report on psoriasis 2016 [cited March 2020]. https:\/\/apps.who.int\/iris\/handle\/10665\/204417. Accessed Mar 2020."},{"key":"1522_CR8","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1136\/annrheumdis-2018-214065","volume":"78","author":"P Sewerin","year":"2019","unstructured":"Sewerin P, Brinks R, Schneider M. Prevalence and incidence of psoriasis and psoriatic arthritis. Ann Rheum Dis. 2019;78:286\u20137.","journal-title":"Ann Rheum Dis"},{"key":"1522_CR9","unstructured":"Doria A, Zavaglia D. Monotherapy is a relevant option in rheumatoid arthritis treatment: a literature review. Clin Exp Rheumatol. 2019. (epub ahead of print)."},{"issue":"1","key":"1522_CR10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s00393-012-1093-6","volume":"72","author":"J Wollenhaupt","year":"2013","unstructured":"Wollenhaupt J, Albrecht K, Kruger K, Muller-Ladner U. The new 2012 German recommendations for treating rheumatoid arthritis: differences compared to the European standpoint. Z Rheumatol. 2013;72(1):6\u20139.","journal-title":"Z Rheumatol"},{"issue":"6","key":"1522_CR11","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2020-217811","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685\u201399.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1522_CR12","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700\u201312.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1522_CR13","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1136\/ard.2008.094946","volume":"68","author":"CT Ritchlin","year":"2009","unstructured":"Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009;68(9):1387\u201394.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1522_CR14","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00403-007-0744-y","volume":"299","author":"A Nast","year":"2007","unstructured":"Nast A, Kopp I, Augustin M, et al. German evidence-based guidelines for the treatment of psoriasis vulgaris (short version). Arch Dermatol Res. 2007;299(3):111\u201338.","journal-title":"Arch Dermatol Res"},{"issue":"23","key":"1522_CR15","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","volume":"375","author":"RE Sherman","year":"2016","unstructured":"Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence\u2014what is it and what can it tell us? N Engl J Med. 2016;375(23):2293\u20137.","journal-title":"N Engl J Med"},{"issue":"2","key":"1522_CR16","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/cpt.1086","volume":"104","author":"H Yuan","year":"2018","unstructured":"Yuan H, Ali MS, Brouwer ES, et al. Real-world evidence: what it is and what it can tell us according to the International Society for Pharmacoepidemiology (ISPE) Comparative Effectiveness Research (CER) Special Interest Group (SIG). Clin Pharmacol Ther. 2018;104(2):239\u201341.","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"1522_CR17","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00296-016-3448-9","volume":"36","author":"N Gossen","year":"2016","unstructured":"Gossen N, Jacob L, Kostev K. Second-line therapy with biological drugs in rheumatoid arthritis patients in German rheumatologist practices: a retrospective database analysis. Rheumatol Int. 2016;36(8):1113\u20138.","journal-title":"Rheumatol Int"},{"issue":"10","key":"1522_CR18","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1111\/jdv.13150","volume":"29","author":"PC van de Kerkhof","year":"2015","unstructured":"van de Kerkhof PC, Reich K, Kavanaugh A, et al. Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey. J Eur Acad Dermatol Venereol. 2015;29(10):2002\u2013100.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1522_CR19","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/bjd.16332","volume":"179","author":"CEM Griffiths","year":"2018","unstructured":"Griffiths CEM, Jo SJ, Naldi L, et al. A multidimensional assessment of the burden of psoriasis: results from a multinational dermatologist and patient survey. Br J Dermatol. 2018;179(1):173\u201381.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1522_CR20","doi-asserted-by":"publisher","first-page":"16068","DOI":"10.1038\/s41598-018-34293-y","volume":"8","author":"PT Lin","year":"2018","unstructured":"Lin PT, Wang SH, Chi CC. Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence. Sci Rep. 2018;8(1):16068.","journal-title":"Sci Rep"},{"issue":"8","key":"1522_CR21","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1080\/09546634.2019.1610553","volume":"31","author":"J Barker","year":"2020","unstructured":"Barker J, Girolomoni G, Egeberg A, Goncalves J, Pieper B, Kang T. Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience. J Dermatol Treat. 2020;31(8):794\u2013800.","journal-title":"J Dermatol Treat."},{"issue":"9","key":"1522_CR22","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1111\/jdv.14937","volume":"32","author":"CEM Griffiths","year":"2018","unstructured":"Griffiths CEM, Augustin M, Naldi L, et al. Patient\u2013dermatologist agreement in psoriasis severity, symptoms and satisfaction: results from a real-world multinational survey. J Eur Acad Dermatol Venereol. 2018;32(9):1523\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1522_CR23","doi-asserted-by":"crossref","unstructured":"Callhoff J, Albrecht K, Hoffmann F, Poddubnyy D, Gunther KP, Zink A. Reality of care for musculoskeletal diseases at the population level: results of the PROCLAIR collaborative project. Z Rheumatol. 2019;78(Suppl 2):73\u20139.","DOI":"10.1007\/s00393-019-0669-9"},{"key":"1522_CR24","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","volume":"8","author":"E Hernlund","year":"2013","unstructured":"Hernlund E, Svedbom A, Ivergard M, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 2013;8:136.","journal-title":"Arch Osteoporos."},{"key":"1522_CR25","unstructured":"International Osteoporosis Foundation. Broken bones, broken lives: a roadmap to solve the fragility fracture crisis in Europe [cited March 2020]. https:\/\/share.iofbonehealth.org\/EU-6-Material\/Reports\/IOF%2520Report_EU.pdf. Accessed Mar 2020."},{"issue":"5","key":"1522_CR26","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.revmed.2012.11.005","volume":"34","author":"K Briot","year":"2013","unstructured":"Briot K, Roux C. Corticosteroid-induced osteoporosis. Rev Med Interne. 2013;34(5):315\u201323.","journal-title":"Rev Med Interne"},{"issue":"9","key":"1522_CR27","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1093\/rheumatology\/35.9.879","volume":"35","author":"T Pincus","year":"1996","unstructured":"Pincus T, Griffith J, Pearce S, Isenberg D. Prevalence of self-reported depression in patients with rheumatoid arthritis. Br J Rheumatol. 1996;35(9):879\u201383.","journal-title":"Br J Rheumatol"},{"issue":"6","key":"1522_CR28","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1007\/s10067-006-0407-y","volume":"26","author":"A Isik","year":"2007","unstructured":"Isik A, Koca SS, Ozturk A, Mermi O. Anxiety and depression in patients with rheumatoid arthritis. Clin Rheumatol. 2007;26(6):872\u20138.","journal-title":"Clin Rheumatol"},{"issue":"6","key":"1522_CR29","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2217\/ijr.11.62","volume":"6","author":"M Margaretten","year":"2011","unstructured":"Margaretten M, Julian L, Katz P, Yelin E. Depression in patients with rheumatoid arthritis: description, causes and mechanisms. Int J Clin Rheumtol. 2011;6(6):617\u201323.","journal-title":"Int J Clin Rheumtol"},{"issue":"7","key":"1522_CR30","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/pds.4202","volume":"26","author":"K Jobski","year":"2017","unstructured":"Jobski K, Luque Ramos A, Albrecht K, Hoffmann F. Pain, depressive symptoms and medication in German patients with rheumatoid arthritis\u2014results from the linking patient-reported outcomes with claims data for health services research in rheumatology (PROCLAIR) study. Pharmacoepidemiol Drug Saf. 2017;26(7):766\u201374.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"1522_CR31","first-page":"891","volume":"146","author":"SK Kurd","year":"2010","unstructured":"Kurd SK, Troxel AB, Crits-Christophe P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis. Arch Dermatol. 2010;146(8):891\u20135.","journal-title":"Arch Dermatol"},{"key":"1522_CR32","doi-asserted-by":"publisher","first-page":"887","DOI":"10.3899\/jrheum.130797","volume":"41","author":"E McDonough","year":"2014","unstructured":"McDonough E, Ayearst R, Eder L, et al. Depression and anxiety in psoriatic disease: prevalence and associated factors. J Rheumatol. 2014;41:887\u201396.","journal-title":"J Rheumatol"},{"key":"1522_CR33","doi-asserted-by":"crossref","unstructured":"Rosa JE, Garc\u00eda MV, Luissi A, et al. Rheumatoid arthritis patient's journey: delay in diagnosis and treatment. J Clin Rheumatol. 2020;26(7S Suppl 2):S148\u201352.","DOI":"10.1097\/RHU.0000000000001196"},{"issue":"Suppl 2","key":"1522_CR34","first-page":"1333","volume":"76","author":"S Moyano","year":"2017","unstructured":"Moyano S, Brom M, Mollerach F, et al. AB0789 The psoriatic arthritis patient's journey: special emphasis on diagnosis and treatment delays. Ann Rheum Dis. 2017;76(Suppl 2):1333.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1522_CR35","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, Landew\u00e9 R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492\u2013509.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1522_CR36","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1136\/ard.2009.126532","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen JS, Landew\u00e9 R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69(6):964\u201375.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1522_CR37","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/nrrheum.2016.183","volume":"12","author":"L Gossec","year":"2016","unstructured":"Gossec L, Coates LC, de Wit M, et al. Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations. Nat Rev Rheumatol. 2016;12(12):743\u201350.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"1522_CR38","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1136\/annrheumdis-2011-200350","volume":"71","author":"L Gossec","year":"2012","unstructured":"Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012;71(1):4\u201312.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1522_CR39","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","volume":"75","author":"L Gossec","year":"2016","unstructured":"Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75(3):499\u2013510.","journal-title":"Ann Rheum Dis"},{"key":"1522_CR40","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s41927-019-0090-7","volume":"3","author":"A Mian","year":"2019","unstructured":"Mian A, Ibrahim F, Scott DL. A systematic review of guidelines for managing rheumatoid arthritis. BMC Rheumatol. 2019;3:42.","journal-title":"BMC Rheumatol"},{"issue":"1085","key":"1522_CR41","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1136\/postgradmedj-2015-133419","volume":"92","author":"D Wcislo-Dziadecka","year":"2016","unstructured":"Wcislo-Dziadecka D, Zbiciak-Nylec M, Brzezinska-Wcislo L, Mazurek U. TNF-alpha in a molecularly targeted therapy of psoriasis and psoriatic arthritis. Postgrad Med J. 2016;92(1085):172\u20138.","journal-title":"Postgrad Med J"},{"issue":"10061","key":"1522_CR42","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1016\/S0140-6736(16)31651-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Burmester G-R, Combe B, et al. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. Lancet. 2016;388(10061):2763\u201374.","journal-title":"Lancet"},{"issue":"1","key":"1522_CR43","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00296-015-3348-4","volume":"36","author":"R Lyu","year":"2016","unstructured":"Lyu R, Govoni M, Ding Q, et al. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany. Rheumatol Int. 2016;36(1):143\u201353.","journal-title":"Rheumatol Int"},{"issue":"7","key":"1522_CR44","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1007\/s12325-019-00969-8","volume":"36","author":"J Mahlich","year":"2019","unstructured":"Mahlich J, Alba A, Hadad LE, Leisten M-K, Peitsch WK. Drug survival of biological therapies for psoriasis treatment in germany and associated costs: a retrospective claims database analysis. Adv Ther. 2019;36(7):1684\u201399.","journal-title":"Adv Ther"},{"issue":"1","key":"1522_CR45","doi-asserted-by":"publisher","first-page":"e000788","DOI":"10.1136\/openhrt-2018-000788","volume":"5","author":"AJ Camm","year":"2018","unstructured":"Camm AJ, Fox KAA. Strengths and weaknesses of \u2018real-world\u2019 studies involving non-vitamin K antagonist oral anticoagulants. Open Heart. 2018;5(1):e000788.","journal-title":"Open Heart"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01522-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-020-01522-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01522-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,11]],"date-time":"2021-04-11T13:12:07Z","timestamp":1618146727000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-020-01522-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,30]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["1522"],"URL":"https:\/\/doi.org\/10.1007\/s12325-020-01522-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,30]]},"assertion":[{"value":"14 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}